Lung

A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab (MK-3475) for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

A Phase II Study of Concurrent Chemoradiation Plus Durvalumab (MEDI4736) Followed by Surgery Followed by Adjuvant Durvalumab (MEDI4736) in Medically Operable Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Induction durvalumab followed by chemoradiation and consolidation durvalumab (MEDI4736) for stage III non-small cell lung cancer

A Phase II Study of GT103 in Combination with Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous, Non-squamous or Not Otherwise Specified NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Chemotherapy and Atezolizumab for Patients with Extensive Stage Small Cell Lung Cancer (SCLC) with Untreated, Asymptomatic Brain Metastases (HCRN LUN19-427)

A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients with Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy

A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029

Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium. BTCRC-LUN17-127

A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

A Phase I/II Study of Carboplatin/Nab-Paclitaxel and MK-3475 for Advanced Non-Small Cell Lung Cancer (NSCLC): LUN13-175  

Phase II Study of Concurrent Pemetrexed and Radiation for Stage III Non-Small Cell Lung Cancer

A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies

Protocol H6Q-MC-S034(a) Randomized, Double-Blind, Phase 2 Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Chemonaive Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113

A Phase II Trial of Concurrent Cisplatin/ Etoposide/ Radiotherapy Followed by Consolidation Sorafenib in Patients with Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC)

Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study

A Phase I-IIa Dose-Ranging Study of Pemetrexed (Alimta) Plus Cetuximab (Erbitux) in Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN04-79

Pemetrexed (Alimta) in Patients with Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer

A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer

A Phase II Trial of Gefitinib (Iressa®) Plus Celecoxib (Celebrex®) in Chemotherapy-naïve Patients with Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC)

A Phase II Trial of ZD1839 (IRESSA®) in Both Patients with Chemosensitive and Chemorefractory Relapsed Neuroendocrine Cancers

Phase Ib/IIa Study of an Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination with Carboplatin-Paclitaxel in Patients with Chemo-therapy Naïve Advanced Non Small Cell Lung Cancer

A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With or Without Consolidation Docetaxel in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN01-24

A Phase III Randomized Study of Taxotere 75/mg/M2 vs. ALIMTA for Second-line Chemo for Non-Small Cell Lung Cancer

A Randomized, Phase III Trial Comparing CPT-11/ Cisplatin with Etoposide/Cisplatin in Patients with Previously Untreated, Extensive Small-Cell Lung Cancer

A Phase II Study of Weekly Paclitaxel Plus Gemcitabine in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase II Study of Taxol + Carboplatin + Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer

A Phase II Study of Carboplatin plus Gemcitabine in Metastatic Non-Small Cell Lung Cancer

A Phase II Study of Paclitaxel (3-Hour Infusion and Bolus Doxorubicin in Recurrent or Refractory Small Cell Lung Cancer

A Phase III Study of Gemcitabine +Cisplatin vs Cisplatin Alone in Patients with Metastatic Non-Small Cell Lung Cancer

A Phase II Study of Gemcitabine + Cisplatin in Non-Small Cell Lung Cancer

A Phase II Study of VP-16 plus Ifosfamide plus Cisplatin (VIP) plus Concurrent Radiation Therapy for Previously Untreated Limited Small Cell Lung Cancer

A Phase III Trial of Maintenance Daily Oral VP-16 vs no Further Therapy Following Induction Chemotherapy with VP-16 plus Ifosfamide plus Cisplatin (VIP) in Extensive Small Cell Lung Cancer

A Phase II Trial of CODE + G-CSF in Advanced NSCL

A Randomized Phase III Study of Definitive Radiation Therapy with or without Hydroxyurea in Previously Untreated Limited Unresectable Non-Small Cell Lung Cancer

Phase II Trial of Carboplatin plus Interferon Alpha-2a in Advanced Non-Small Cell Lung Cancer

Phase II Study of VP-16 Plus Ifosfamide Plus Cisplatin (VIP) as Combination Chemotherapy for Previously Treated Small Cell Lung Cancer

Phase II Trial of Daily Oral Etoposide in Advanced Non-Small Cell Lung Cancer

Phase II Trial of Daily Oral Etoposide in Refractory Small Cell Lung Cancer

Phase III Study of VP-16 + Cisplatin Alone (VP) + Ifosfamide (VIP) for Previously Untreated Extensive Small Cell Lung Cancer

A Phase II Trial of VP-16, Ifosfamide and Cisplatin (VIP) Combination Chemotherapy for Previously Untreated Extensive Small Cell Lung Cancer

A Randomized Phase III Study Of Definitive Radiation Therapy With/Without Cisplatinum in Previously Untreated Inoperable Non-Metastatic Non-Small Cell Lung Cancer

Phase II Study of Vinblastine VP-16 (Etoposide), and Cisplatin (VEP) for Patients with Extensive Non-Small Cell Lung Cancer

A Phase II Trial of VP-16 and Split-Dose Cisplatin in Extensive Small Cell Lung Cancer

Phase III Study of Split Dose Cisplatinum Plus VP-16 in the Treatment of Locally Recurrent or Metastatic Non-Small Cell Lung Cancer